利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

40 条记录 (耗时 0.046 秒)

    Recombinant yeast transformant and process for preparing immunoglobulin Fc fragment employing the same
    31.
    发明授权
    Recombinant yeast transformant and process for preparing immunoglobulin Fc fragment employing the same 有权
    重组酵母转化体及使用其制备免疫球蛋白Fc片段的方法

    公开(公告)号：US09394546B2

    公开(公告)日：2016-07-19

    申请号：US14763722

    申请日：2014-02-03

    申请人： HANMI PHARM. CO., LTD.

    发明人： Jin-Sun Kim ,  Yong Ho Huh ,  Euh Lim Oh ,  Min Young Kim ,  Sung Youb Jung ,  Se Chang Kwon

    IPC分类号： C12N1/15 ,  C12P21/04 ,  C12N15/81 ,  C07K16/00

    CPC分类号： C12N15/815 ,  C07K16/00 ,  C07K2317/14 ,  C07K2317/52 ,  C12N15/81

    摘要： The present invention relates to a transformant prepared by introducing an expression vector comprising a polynucleotide encoding for a human immunoglobulin Fc fragment into Pichia sp. yeast, a method for producing an immunoglobulin Fc fragment comprising culturing the transformant, and recovering the immunoglobulin Fc fragment from the culture, and an immunoglobulin Fc fragment, prepared by the above method for use as a drug carrier. The transformant is suggested as a solution to the problems associated with the use of E. coli or animal cells as hosts for producing immunoglobulin Fc fragments useful as drug carriers, so that it can find various applications in the effective and economical production of drugs.

    摘要翻译： 本发明涉及通过将包含编码人免疫球蛋白Fc片段的多核苷酸的表达载体导入毕赤酵母（Pichia sp。）而制备的转化体。 酵母，生产免疫球蛋白Fc片段的方法，包括培养转化体，从培养物中回收免疫球蛋白Fc片段，以及通过上述方法制备的免疫球蛋白Fc片段作为药物载体。 建议转化体作为解决与使用大肠杆菌或动物细胞作为用于产生用作药物载体的免疫球蛋白Fc片段的宿主相关的问题的解决方案，从而可以在药物的有效和经济生产中找到各种应用。

    Glucagon derivatives with improved stability
    35.
    发明授权
    Glucagon derivatives with improved stability 有权

    公开(公告)号：US10881715B2

    公开(公告)日：2021-01-05

    申请号：US15540729

    申请日：2015-12-30

    申请人： HANMI PHARM. CO., LTD.

    发明人： Jung Kuk Kim ,  Jong Min Lee ,  Sang Yun Kim ,  Sung Min Bae ,  Sung Youb Jung ,  Se Chang Kwon

    IPC分类号： A61K38/26 ,  C07K14/605 ,  A61K45/06

    摘要： The present invention relates to a novel glucagon derivative peptide, and a composition for preventing or treating hypoglycemia containing the novel glucagon derivative peptide as an active ingredient. The glucagon derivative according to the present invention has improved physical properties due to the change in isoelectric point (pI) while being capable of maintaining an activity on glucagon receptors, and thus can improve patient compliance when used as a hypoglycemic agent, and is also suitable for administration in combination with other anti-obesity agents. Accordingly, the glucagon derivative according to the present invention can be effectively used for the prevention and treatment of hypoglycemia and obesity.

    Insulinotropic peptide derivative with modified N-terminal charge
    40.
    发明授权
    Insulinotropic peptide derivative with modified N-terminal charge 有权

    公开(公告)号：US09663565B2

    公开(公告)日：2017-05-30

    申请号：US14758842

    申请日：2014-01-03

    申请人： HANMI PHARM. CO., LTD.

    发明人： Sung Youb Jung ,  Sang Youn Hwang ,  In Young Choi ,  Sung Hee Park ,  Se Chang Kwon

    IPC分类号： C07K14/605 ,  C07K14/575 ,  C07K14/62 ,  A61K38/22 ,  A61P7/12

    CPC分类号： C07K14/605 ,  C07K14/575 ,  C07K14/62

    摘要： The present invention relates to an insulinotropic peptide derivative with a modified N-terminal charge and a pharmaceutical composition including the same. Specifically, the insulinotropic peptide derivative is characterized in that the N-terminal positive charge of the insulinotropic peptide is modified to a neutral or net negative charge at neutral pH. The insulinotropic peptide derivative according to the present invention is rapidly dissociated from the GLP-1 receptor owing to the above modification in the N-terminal charge, and exhibits enhanced insulinotropic ability and blood glucose-lowering activity compared to the native insulinotropic peptide while maintaining its stability in blood. Accordingly, the insulinotropic peptide derivative of the present invention is very useful for the treatment of type 2 diabetes.